iiinova — where your digital self keeps evolving

PolyBio Research Foundation @polybiorf.bsky.social · 14/08/2026

Featured in Bloomberg this week: UCSF’s PolyBio-supported LIINC team and their recent preprint suggesting SARS-CoV-2 viral and protein persistence in the gastrointestinal tracts of a portion of Long COVID patients. 1/

1289

PolyBio Research Foundation @polybiorf.bsky.social · 10/08/2026

PolyBio is supporting research that investigates the bone marrow as a potential long-term SARS-CoV-2 reservoir site. Bone marrow-derived cells, including megakaryocytes and the platelets they produce, have previously been shown to contain SCV2 double-stranded RNA in Long COVID patients’ samples— 1/

1179

PolyBio Research Foundation @polybiorf.bsky.social · 17/07/2026

Dr. Amy Proal in collaboration with the Cohen Center for Recovery from Complex Chronic Illness this week: “A big goal of ours is that [Long COVID] diagnostics are available to be ordered in insurance care for the most number of patients…

171

PolyBio Research Foundation @polybiorf.bsky.social · 16/06/2026

This PolyBio-supported project is determining underlying genetic causes, and other modifying factors like sex hormones and interferon responses, impacting restrained T cell responses to SARS-CoV-2 & viral persistence in LongCOVID.

Genetic variants and antiviral immunity in severe long COVID. Three pink DNA double stranded molecules surround a bright pink coronavirus.

120

PolyBio Research Foundation @polybiorf.bsky.social · 16/06/2026

“What we’re finding across the genome are specific variants that are very much enriched, and have highly likely loss-of-function in these patients with [severe] Long COVID,” said Dr. Petter Brodin on his team’s PolyBio-supported genome study of Long COVID patients.

1182

PolyBio Research Foundation @polybiorf.bsky.social · 01/06/2026

Written summaries of PolyBio’s Spring symposium presentations are available now! Check out shortened, simplified summaries, or full technical explanations of your favourite research projects. 2026-spring-symposium-polybio.netlify.app #Longcovidresearch #mecfsresearch #chroniclymedisease

0199

PolyBio Research Foundation @polybiorf.bsky.social · 29/05/2026

Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Clinical Trial with a New Open-Label Phase 1/

13610

PolyBio Research Foundation @polybiorf.bsky.social · 08/05/2026

Catch Dr. Michael Peluso, part of the PolyBio-supported Long COVID tissue bank & LIINC collaborative, in Men’s Health this week! Read the full article here: www.menshealth.com/health/a7113... #longcovidtreatment #longcovidresearch #menshealth

092

PolyBio Research Foundation @polybiorf.bsky.social · 27/04/2026

PolyBio today announced a $10M donation to support the Long COVID Cure Initiative, a program designed to deliver treatments to millions of Long COVID patients by translating academic findings into real-world diagnostic tests, more targeted clinical trials, and accessible, patient-ready therapies.

Our PolyBio LCCI strategy has four steps: 1. Validate diagnostics, 2. Commercialize diagnostics, 3. Mobilize smarter trials and 4. Scale up clinical adoption. The result is that millions of patients receive viable treatment years sooner.

141

PolyBio Research Foundation @polybiorf.bsky.social · 27/04/2026

Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative The funding will fast-track Long COVID diagnostics and treatments 🧵 www.prnewswire.com/news-release...

A man with reddish-brown hair wears a blue surgical mask and lab goggles. He looks through a lab hood and pipettes liquid underneath the hood.

12710

PolyBio Research Foundation @polybiorf.bsky.social · 21/04/2026

Save the date! PolyBio’s Spring symposium will take place on Friday, May 22 11-5 PM ET. It will feature project updates on Long COVID, ME/CFS, Alzheimer’s & chronic tick-borne disease research that is advancing how we diagnose & treat IACIs. Sign up now: us02web.zoom.us/webinar/regi...

0135

PolyBio Research Foundation @polybiorf.bsky.social · 24/03/2026

“Having witnessed how a single test can transform a complex disease like HIV, I am fully committed to doing my part to develop tests for Long COVID,” said Steven Deeks MD, Professor of Medicine at UCSF and a senior investigator in LIINC and VIPER.

Steve Deeks, a man with short-cropped hair and white skin, is wearing a pale purple button-down shirt and green pants. He is leaning back on a hospital bed surrounded by IV poles and medical machines.

1144

PolyBio Research Foundation @polybiorf.bsky.social · 24/03/2026

BREAKING: VIPER Diagnostics Program Launches as First Phase of PolyBio Long COVID Cure Initiative Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.

A scientist with red, short hair and white skin sits at a computer screen evaluating a microscope slide. They are wearing a blue surgical mask. A large microscope sits on the desk beside them.

22116

PolyBio Research Foundation @polybiorf.bsky.social · 23/03/2026

PolyBio Research Foundation is keeping you in-the-know with our newly launched newsletter! Sign up for our mailing list to get direct project updates to your inbox & meet the team that drives our research forward. polybio.org/newsletter/

086

PolyBio Research Foundation @polybiorf.bsky.social · 25/02/2026

Interested in low-dose Rapamycin for Long Covid? The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for a RCT of the mTOR inhibitor Sirolimus (Rapamycin). The trial aims to evaluate if changes to the immune response as a result of the drug improve Long Covid symptoms.

11813

PolyBio Research Foundation @polybiorf.bsky.social · 13/02/2026

1/ Long Covid, ME/CFS and Post-Treatment Lyme patients living in NYC: Mount Sinai’s CoRE clinic is actively recruiting for a clinical trial of Lumbrokinase. This enzyme breaks down fibrin, a coagulation factor linked to chronic symptoms,

1198

PolyBio Research Foundation @polybiorf.bsky.social · 09/02/2026

PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)

1110

PolyBio Research Foundation @polybiorf.bsky.social · 31/01/2026

PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit. polybio.org/polybio-scie...

1192

PolyBio Research Foundation @polybiorf.bsky.social · 27/01/2026

Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.

1153

PolyBio Research Foundation @polybiorf.bsky.social · 12/01/2026

Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.

120

PolyBio Research Foundation @polybiorf.bsky.social · 12/01/2026

“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.

13011

PolyBio Research Foundation @polybiorf.bsky.social · 02/01/2026

Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.

1141

PolyBio Research Foundation @polybiorf.bsky.social · 01/01/2026

To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.

1131

PolyBio Research Foundation @polybiorf.bsky.social · 31/12/2025

No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments. #polybio2026countdown

030

PolyBio Research Foundation @polybiorf.bsky.social · 30/12/2025

PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.

181

PolyBio Research Foundation @polybiorf.bsky.social · 29/12/2025

No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.

283

PolyBio Research Foundation @polybiorf.bsky.social · 28/12/2025

No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS. #polybio2026countdown

291

PolyBio Research Foundation @polybiorf.bsky.social · 28/12/2025

2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic. #polybio2026countdown

1111

PolyBio Research Foundation @polybiorf.bsky.social · 26/12/2025

One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging. “As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.” #polybio2026countdown

281

PolyBio Research Foundation @polybiorf.bsky.social · 23/12/2025

A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials. www.latimes.com/opinion/stor... #polybio #polybio2026countdown

062

PolyBio Research Foundation @polybiorf.bsky.social · 20/12/2025

Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.

1111

PolyBio Research Foundation @polybiorf.bsky.social · 19/12/2025

You can help PolyBio ensure that our impactful work continues by pledging to be a “PolyBio Persister.” Those in the Persister Program make a 3-year commitment to supporting our research on infection-associated chronic illness. Consider joining today! polybio.org/wp-content/u...

010

PolyBio Research Foundation @polybiorf.bsky.social · 19/12/2025

Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown

170

PolyBio Research Foundation @polybiorf.bsky.social · 18/12/2025

Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵

140

PolyBio Research Foundation @polybiorf.bsky.social · 17/12/2025

Today at the HHS Invisible Illness roundtable: Dr. Amy Proal (PolyBio President & Scientific Director of the CoRE clinic) with 60 Degrees Pharma CEO, Dr. Geoffrey Dow. Dr.s Proal & Dow were part of the crucial discussion to address gaps in Lyme disease diagnostics & treatment.

A woman with long blonde hair in a black blazer (Dr Amy Proal) stands on the left of a sign that says Lyme Disease roundtable on an easel. A man with brown hair, wearing a pink button up shirt and brown blazer stands on the right of the sign.

150

PolyBio Research Foundation @polybiorf.bsky.social · 16/12/2025

2/Read the paper here: pubmed.ncbi.nlm.nih.gov/39947217/

032

PolyBio Research Foundation @polybiorf.bsky.social · 16/12/2025

One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid. #polybio2026countdown

152

PolyBio Research Foundation @polybiorf.bsky.social · 15/12/2025

We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown

020

PolyBio Research Foundation @polybiorf.bsky.social · 14/12/2025

We are excited to announce that PolyBio core team members Dr. Amy Proal & Dr. David Putrino are leading a clinical trial of tafenoquine for treatment of chronic babesiosis, in partnership with 60 Degrees Pharma. The trial will take place at Mount Sinai’s CoRE clinic & will treat up to 100 patients.

160

PolyBio Research Foundation @polybiorf.bsky.social · 12/12/2025

2/ Circulating spike protein, potentially leaking from SARS-CoV-2 reservoirs, was detected in blood from a subset of children. We are supporting a clinical trial in Long COVID children, to test if the drug Larazotide can reduce gut barrier permeability, thereby stopping spike leakage into blood.

1112

PolyBio Research Foundation @polybiorf.bsky.social · 12/12/2025

1/ PolyBio supports research & treatment for children with Long COVID. This year, a study by our team at Harvard Medical School found that neutrophil immune cells from children with Long Covid were hyperactive and associated with pro-inflammatory pathway signaling.

13317

PolyBio Research Foundation @polybiorf.bsky.social · 11/12/2025

3/ PolyBio also awarded $1M to UCSF to expand the LIINC program into ME/CFS, using tissue biopsy and advanced ImmunoPET-CT imaging to study viral persistence and immune activation in the brain, spinal cord, and bone marrow.

160

PolyBio Research Foundation @polybiorf.bsky.social · 11/12/2025

How PolyBio is driving forward ME/CFS research🧵 In 2025, PolyBio’s cofounders helped identify biomarkers that divide ME/CFS patients into two subgroups. One group had elevated MMPs/cytokines consistent with CNS inflammation; the other showed unique immune correlations linked to joint hypermobility.

1182

PolyBio Research Foundation @polybiorf.bsky.social · 10/12/2025

“We sought out Amy & PolyBio because we cannot afford less than the best knowledge & information to help guide our [mAb trials],” said Invivyd chairman Marc Elia. PolyBio has funded 4+ clinical trials & most recently is supporting sample analysis for a RCT of Anktiva in Long Covid.

284

PolyBio Research Foundation @polybiorf.bsky.social · 20/05/2025

PolyBio and WE&ME supported study identifies two distinct ME/CFS subtypes 🧪Collaborative research uncovers immune and biomarker patterns that could help subclassify ME/CFS and guide future treatments. polybio.org/polybio-and-...

$An outline of a human body divided into 2 halves. The left side is pink and represents cluster 1 of the ME/CFS cohort. There was an increase in MMP1, 2 and 10 in the cerebrospinal fluid. There was an increase in inflammatory cytokines and an observed fractalkine mismatch. There was also an increase in CMV seropositivity. In cluster 2 in blue on the right, there was a decrease in MMPs and inflammatory cytokines. Fractalkine correlated well with MMP2. There is also a higher seropositivity to SARS CoV 2 and parvovirus B19.$

48129

PolyBio Research Foundation @polybiorf.bsky.social · 08/05/2025

PolyBio’s Spring Symposium is approaching fast—on May 16, watch exciting project updates on clinical trials, tissue pipelines, immune & metabolism findings on infection-associated chronic illnesses. Sign up now: us02web.zoom.us/webinar/regi...

34118

PolyBio Research Foundation @polybiorf.bsky.social · 02/05/2025

Post-treatment Lyme Disease patients with chronic pain in the US—consider participating in this decentralized study (completely virtual). It’s run via the CoRE clinic under the direction of Drs. David Putrino and Amy Proal @putrinolab.bsky.social @coresinai.bsky.social

0206

PolyBio Research Foundation @polybiorf.bsky.social · 01/05/2025

The PolyBio-supported study on elevated plasma proteins associated with breathlessness in Long COVID was featured in an article in Technology Networks : www.technologynetworks.com/tn/news/long...

13010

PolyBio Research Foundation @polybiorf.bsky.social · 18/04/2025

Calling all Long Covid, ME/CFS and Post-Treatment Lyme patients in the Boston area! This PolyBio-supported study is now seeking participants. Participants must be able to attend an in-person visit at Brigham & Women’s hospital in Boston to participate. Email dsaadi@mgh.harvard.edu if interested

02010

PolyBio Research Foundation @polybiorf.bsky.social · 15/04/2025

We’re truly excited that the PolyBio supported Low-dose Rapamycin trial is now recruiting in the NYC area. Interested in learning more? Here’s the full study summary: polybio.org/projects/lon...

Flyer for Long Covid clinical trial of low dose rapamycin. Researchers are investigating effects of a 12 week course of low dose Sirolimus (Rapa) bs placebo in adults with Long Covid. You’re eligible if you have a positive test for COVID and a diagnosis of long covid. There are 5 in person visits required over the 6 month study period. There are blood draws, in person meetings, saliva collection and online surveys required. If you’re interested, please email coreresearch@mountsinai.org.

15836